Second International Congress Drug Therapy in HIV Infection 18-22 November 1994 Glasgow, UK

DISTINCT CHANGES IN HIV-1 RNA VERSUS P24 IN SERUM DURING SHORT-TERM ZIDOVUDINE THERAPY IN ASYMPTOMATIC INDIVIDUALS WITH AND WITHOUT PROGRESSION TO AIDS

S. Jurriaans, G.J. Weverling, J. Goudsmit, J. Boogaard, M. Brok, D. van Strijp, M. Koot and B. van Gemen
AMC, Meibergdreef 15,Amsterdam, The Netherlands and Organon Teknika, Boseind 15, Boxtel, The Netherlands

Int Cong Drug Therapy HIV 1994 Nov 18-22;2:Abstract No. 2.6
AIDS 1994, Vol. 8 (Suppl. 4);S2

Serum HIV-1 RNA and p24 antigen levels were examined in 29 seropositive asymptomatic individuals participating in a trial on the efficacy of zidovudine. Quantitation of HIV-1, ANA was done using the one-tube Q.NASBA technology based on the co-amplification of 3 internal standard RNAs with the wild-type HIV-1, ANA. Serum HIV-1, RNA and p24 antigen levels were determined before the onset of therapy and during the first8 weeks of therapy to establish whether the patterns of change were predictive of clinical outcome. Up till4 years after the onset of therapy, 7 individuals remained asymptomatic, whereas 12 individuals-progressed to AIDS. Among the 29 participants 52% had measurable pre-treatment concentrations of p24 antigen. Initiation of zidovudine therapy was followed by a similar decline of p24 antigen levels in non-progressors as well as progressors and therefore these groups could not be distinguished on the basis of this parameter. In the group of non-progressors HIV-1, ANA declined significantly during the first 4 weeks of therapy and remained below pre-treatment levels at 8 weeks of therapy in both p24 positive and p24 negative individuals. In the progressors positive for p24 antigen HIV-1 RNA levels did not change significantly, whereas the p24 negative progressors showed a significant decline of HIV-1, RNA in the first 4 weeks and a rebound to pre-treatment levels at 8 weeks of therapy. Our data indicate that HIV-1, RNA quantification is a superior way to evaluate antiviral efficacy using disease progression as end-point. compared to p24 antigen quantification.

Presenting author: B. van Gemen

1994-11-18
2.6

Originally published in AIDS Volume 8, Supplement 4 and hosted with permission of the publisher Lippincott Williams & Wilkins, 250 Waterloo Road, London, SE1 8RD, UK. Tel: +44 (0)20 7981 0700 Fax: +44 (0) 7981 0701

Copyright © 1994 - Lippincott Williams & Wilkins. All rights reserved. All abstracts from the 2nd International Congress Drug Therapy in HIV Infection, appearing on the AEGiS web site, are protected by United States copyright law and may not be reproduced, distributed, transmitted, displayed, or otherwise published without the prior written permission of Lippincott Williams & Wilkins. You may not alter or remove any trademark, copyright or other notice. However, provided that you maintain all copyright and other notices contained therein, you may download material (one machine readable copy and one print copy per page) for your personal, non-commercial use only.

http://www.aidsonline.com http://www.ovid.com